Team Kendall's Social Media

  • Wix Facebook page
  • Instagram Social Icon

Friedreich's Ataxia Treatment Advancement

January 21, 2014

The Friedreich's Ataxia Research Alliance announced today that BioMarin Pharmaceutical, a company with a strong commitment and success in developing treatments for rare diseases, will be taking the Histone DeACetylase (HDAC) inhibitor program forward. Click here to access FARA's press release as well as a press release from Repligen and BioMarin

 

With this exciting news, we are reminded of the important work our donations fund. Thank you to everyone who has had a part in making this happen. We are moving forward to finding a cure for Friedreich's Ataxia! 

Please reload

Featured Posts

What Fundraising Means to Me

March 7, 2019

1/9
Please reload

recent posts

January 5, 2020

December 18, 2019

December 12, 2019

December 6, 2019

November 26, 2019

November 22, 2019

November 18, 2019

October 17, 2019

Please reload